At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
Retifanlimabdrug
Likely dose
Retifanlimab 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of INCMGA00012 in Advanced Penile Squamous Cell Carcinoma.
In Brief
A Phase 2 clinical trial evaluating Retifanlimab for Penile Cancer. Completed, enrolled 18 participants across 13 sites in 2 countries.
Detailed Summary
This is a multicenter, open-label, single-arm, phase II clinical trial to evaluate the efficacy and safety of INCMGA00012 in Advanced Penile Squamous Cell Carcinoma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPenile Cancer
CountriesItaly, Spain
CollaboratorsIncyte Biosciences International Sàrl
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartApr 2020
Primary CompletionFeb 2022
Study CompletionAug 2022
TodayJul 2026
First PostedJan 18, 2020
Enrollment StartApr 28, 2020
Primary CompletionFeb 15, 2022
Study CompletionAug 26, 2022
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 6.5 years ago
Interventions
Retifanlimabdrug
INCMGA00012 500 mg will be administered on Day1 of each cycle (once every four weeks), for up to 2 years.